New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine
The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically significant reductions in mean monthly migraine days (MMDs) compared with …